PARP inhibition in cancer therapy
Moving in Annals of Oncology, Clinical Cancer Research, Molecular Cancer Therapeutics, bioRxiv, Cell Death & Differentiation, JNCI: Journal of the National Cancer Institute, Nature Communications and Oncogene.
- Moved, week to 17 Nov 2026
- 0
- Papers in 60 days
- 55
Rebuilt
Moved this week
Nothing in this topic has moved yet this week.
Latest in PARP inhibition in cancer therapy
Newest first · last 60 days
AI summary · may contain errors
MGMT promoter methylation predicts progression-free and overall survival in glioblastoma treated with temozolomide, with hazard ratios of 2.07 and 2.13 using methylation-specific PCR and pyrosequencing.
AI summary · may contain errors
BRCA2 reversion mutations that restore function are shaped by local sequence context and BRCA2 domain architecture, determining which reading-frame or splicing events become PARPi-resistant in BRCA2-mutant isogenic cells.
- Open access
AI summary · may contain errors
BRCA1 loss is linked to mitochondrial dysfunction, mtDNA instability, oxidative stress, and inflammatory remodeling, creating therapeutic vulnerabilities beyond homologous recombination deficiency.
AI summary · may contain errors
Loss of ESCO2, a replication-coupled cohesin acetyltransferase, is linked to PARP inhibitor hypersensitivity by promoting G-quadruplex accumulation at fragile pericentromeric replication sites.
AI summary · may contain errors
In the PALLAS phase III trial for stage II–III hormone receptor-positive breast cancer, developing high-grade neutropenia (grade ≥3) on palbociclib plus endocrine therapy is linked to better 5-year invasive disease-free survival than endocrine therapy alone.
AI summary · may contain errors
CDK12-knockout prostate cancer cells show an ATM-like DSB response phenotype and are sensitized to ATR inhibition, with combined PARP plus ATR suppressing growth in CDK12-defective patient-derived xenografts.
- 2 cites
AI summary · may contain errors
In the OlympiA phase III trial of 1836 women with germline BRCA1/BRCA2-associated high-risk HER2-negative early breast cancer, 1-year adjuvant olaparib maintained survival benefits at 6.1 years.
- Open access
- 2 cites
AI summary · may contain errors
The NAD+-PARP1-XRCC1 axis is positioned at the intersection of genome maintenance and metabolic control in ALS, linking oxidative DNA damage and NAD+ depletion to motor neuron degeneration.
- Open access
AI summary · may contain errors
QC-activated cathepsin L drives increased DNA damage in ovarian cancer cells by downregulating RAD51 and 53BP1, impairing homologous recombination repair.
- Open access
AI summary · may contain errors
PTK7 in triple-negative breast cancer scaffolds DNA-PKcs in the nucleus, boosting NHEJ repair and dampening STING-IFN signaling linked to immune evasion.
AI summary · may contain errors
Talazoparib plus enzalutamide achieved a 73% PSA <0.2 ng ml−1 response rate at 12 months in high-volume metastatic hormone-naive prostate cancer, exceeding the prespecified threshold.
- Open access
AI summary · may contain errors
Adding niraparib to pembrolizumab as maintenance in advanced or metastatic NSCLC did not improve progression-free survival, with median PFS 5.55 months in both arms.
- Open access
- 1 cites
AI summary · may contain errors
Gemcitabine plus elimusertib synergistically kills TP53-mutant/ATRX-wildtype uterine leiomyosarcoma cells, with reciprocal potency enhancement at low-nanomolar concentrations and increased apoptosis versus monotherapy.
- Open access
AI summary · may contain errors
OKI-1546–mediated CDK12/13 inhibition induces BRCAness and apoptosis in neuroblastoma cells, and synergizes with merestinib to intensify DNA damage.
- Open access
AI summary · may contain errors
Updated ASCO living guideline evidence for epithelial ovarian cancer links PARPi use to progression-free survival benefits in frontline trials, while later-line and recurrent maintenance trials report potential overall survival disadvantages.
- Open access
AI summary · may contain errors
Atirmociclib plus fulvestrant significantly improved investigator-assessed progression-free survival versus investigator’s choice therapy in HR-positive/HER2-negative advanced breast cancer, with median 9.4 vs 6.6 months.
- Open access
AI summary · may contain errors
Abemaciclib plus fulvestrant in HR-positive, HER2-negative advanced breast cancer after progression on prior CDK4/6 inhibitor plus endocrine therapy showed numerically longer overall survival (32.1 vs 24.6 months; HR 0.80).
- Open access
- 1 cites
AI summary · may contain errors
Ribociclib plus nonsteroidal aromatase inhibitor improved 6-year overall survival versus nonsteroidal aromatase inhibitor alone in HR+/HER2- early breast cancer, with a 2.1% OS difference (HR 0.809).
- Open access
- 1 cites
AI summary · may contain errors
DCA-conjugated, fully chemically stabilized PARP1-selective siRNAs achieved up to 80% PARP1 mRNA knockdown in mouse liver, heart, and skeletal muscle after subcutaneous dosing.
- Open access
AI summary · may contain errors
Carboplatin plus mirvetuximab soravtansine achieved an investigator-assessed objective response rate of 62.7% in recurrent platinum-sensitive ovarian cancer with folate receptor alpha (FRα) ≥50% expression.
- Open access
AI summary · may contain errors
Neoadjuvant olaparib plus pembrolizumab in HRD-positive stage III–IV high-grade serous or endometrioid ovarian cancer achieved a 70% overall response rate (95% CI 45.7–88.1).
- 6 cites
AI summary · may contain errors
In 31 patients with advanced biliary tract cancer receiving rucaparib plus nivolumab maintenance, the 4-month progression-free survival rate was 54.8% (95% CI 36–72.7), not meeting the primary target.
- Open access
AI summary · may contain errors
DNA damage response and biomarker-defined vulnerabilities in recurrent or treatment-resistant gynecological malignancies show encouraging clinical activity, including targets like WEE1, PKMYT1, WRN, and CCNE1 amplification.
AI summary · may contain errors
High MYBL2 expression is critical for triple-negative breast cancer stem/progenitor cell self-renewal and DNA repair, and MYBL2 downregulation impairs stemness in vitro and in vivo.
- Open access
AI summary · may contain errors
An adjacent nucleosome core particle stimulates Polβ strand-displacement synthesis in linker DNA, and this nucleosome context strengthens PARP1/PARP2- and FEN1-dependent regulation of BER sub-pathway choice.
- Open access
Browse JClub
Journals this month
- bioRxiv6412
- medRxiv1763
- PNAS556
- JAMA353
- Sci Adv330
- Cell Rep315
- Environ Res225
- BMJ217
- EHJ206
- Nat Commun172
- NAR172
- Plant Cell Environ167
- Environ Pollution153
- Science152
- Curr Biol148
- NEJM148
- New Phytol147
- Nature128
Topics moving, week to 17 Nov 2026
- Single-cell and spatial transcriptomics10
- Gut microbiota and health6
- CAR-T cell therapy research6
- Pancreatic and Hepatic Oncology Research5
- Genomics and Chromatin Dynamics5
- Inflammatory Bowel Disease5
- Lung Cancer Treatments and Mutations5
- Antibiotic Resistance in Bacteria5
- Genomics and Phylogenetic Studies4
- Lipoproteins and Cardiovascular Health4
By field
- General Science & Medicine22
- Clinical Medicine25
- Cardiology & Vascular Biology12
- Endocrinology & Metabolism10
- Gastroenterology & Hepatology7
- Public & Global Health4
- Cell & Molecular Biology30
- Immunology & Inflammation14
- Neuroscience14
- Psychiatry & Mental Health8
- Genomics & Bioinformatics29
- Pharmacology & Drug Discovery5
- Microbiology & Mycology34
- Oncology22
- Ecology & Evolution5
- Protected Cropping & Horticultural Science5
- Plant Physiology & Photobiology19
- Student Research1
